中国生物医药黄金时代已来,学术转化困境犹存

2020-11-28 JACKZHAO MedSci原创

2020年中国生物医药产业创新大会在沪举行,生物医药当前处于最为重要的发展时期,关键词:转型、耐心、勇气

11月28日,2020年中国生物医药产业创新大会暨第六届生物医药创新及研发国际研讨会在沪举行。本次主题为"创新转化,赋能生物医药产业",将着眼于全球生物医药前沿技术与最新动态,探求助推战略性新兴产业高端攀升的实现路径及对策。

本次主办地上海宝山紧扣建设上海科创中心主阵地定位,不断加快对生物医药产业谋篇布局,今年已有投资总额超100亿元,23个企业项目在北上海生物医药产业园签约、落地。

本次活动也得到了上海市经信委、上海市药监局等诸多生物医药机构大力支持,也汇集了包括中国科学院院士陈凯先、 裴钢院士、刘昌胜、金力、宁光等一众院士在内的诸多顶级专家、学者

中国科学院院士陈凯先先生

中国科学院院士陈凯先接受包括梅斯医学在内媒体表示,生物医药产业发展已成为战略制高点,与科技发展紧密相连,成为必争之地。当前中国面临非常好的机遇与空间,中国生物医药发展水平总量仅次于美国,但人均差异仍然巨大,人均用药增长将具有极大空间。罕见病领域绝对数也不小,健康中国大战略支持下,新冠疫情背景下医疗卫生事业大发展更加紧迫需求。

需要承认当前我国生物医药仍然存在诸多薄弱环节,创新源头上虽已取得较大突破,特别是研发新药水平上具有很大的突破,中国新药研发数已达10个以上,在全球总体几十个体量下具有相当份量,但原始创新仍然不足,作用靶点仍然不是首创,原始创新需要大力加强,目前推动生物医药发展是当前最为重要的发展时期。

中国科学院上海药物研究所所长、新药研究国家重点实验室副主任李佳

中国科学院上海药物研究所所长、新药研究国家重点实验室副主任李佳也表达类似观点。他指出,虽然中国占全球新药20%到25%,但纵观整个生物医药创新,原始新药非常缺乏,绝大是模仿类创新,是新药,但原创靶标,原创概念的提出在中国还是风毛麟角。

但这不妨碍,中国生物医药黄金时代到来,关键词是转型与耐心,还需要勇气。他深信,我国将在2030年会进入跨越阶段,将能够实现两个历史性的转变,从仿制为主走向创新为主,同时从制药大国走向制药强国。FIRST IN CLASS是我们最终的追求。这是我们未来可能从新药上市,从零星突破到密集上市,预计2024年我们销售额比例占非中药的比例达到10%。2029年达到30%。

30年内将有辉瑞罗氏级别跨国药企出现。在百年之大变局下,真正转型也需要极大的勇气。新冠这样的传染病问题,仍然我国面临的终极挑战。

他还指出中国学术转化仍然存在较大困境,2019年全球700篇生命科学领域CNS文章,中国学者就发表了100篇,而今年可能会超过150篇接近200篇。这表明,中国不是没有原始创新成果,但把这些原始创新向新药研发进行桥接过程出现巨大问题。

目前几乎没有任何的CNS文章提出的那些潜在的靶标真的向新药研发进行转化,这是我们非常重要的一个未来要解决的问题。所以我们希望通过国家实验室来解决从发现机制到靶标发现、靶标确证的问题能提供真正的先导分子,同时也希望能活力,对生物医药产业有需求的地方减速产业加速器,来弥补新药开发跟市场转化最终到产品结合的困境。

国家药监局CDE原主任许嘉齐,表示对于后疫情时代,出现了新变化与要求,科学技术驱动的变化必然导致产业发展组织形式发生变化,社会管理与监管模式也将发生根本改变,对生物医药领域是百年之变,让中国发展站在全球角度,需要一种全新模式。中国创新能力有较大提升,中国鼓励创新政策不断更迭提升,对未来创新药企业具有很大机遇。

复星医药董事长吴以芳则认为,应对新变化需要根据疾病谱来考虑开发,追热点研究需要考虑自身能力与优势,微创新等等探索也应量力而行,用开放的思维来做。

会上来自上海市生物医药行业协会、上海市生物医药产业促进中心、上海市银行同业公会、上海市基金同业公会、上海市证券同业公会今日联合还向社会发起倡议,希望本市各金融机构能加大对生物医药企业的支持力度,共同助推上海生物医药产业高质量发展。

下一步,上海宝山将聚焦提升园区产业高度、科创浓度、产出强度为目标,在提升服务企业的同时,通过加快载体建设、探索资本注入、优化平台功能、完善园区配套、招引培育并举等举措,努力将宝山打造成长三角生物医药产业高质量集群发展承载区、上海生物医药产业发展新标杆和中国生物医药产业全产业链发展新高地。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-30 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-29 penhauer

    高瞻远瞩

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-29 15242b3561m

    生物制剂,未来药物的发展方向

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-28 355366180

    加油

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-28 ms7000000371157871

    希望生物医药有更好的前景

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-28 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1707237, encodeId=e6c01e0723796, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sat Jul 10 05:37:57 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037660, encodeId=2ea0203e660dc, content=<a href='/topic/show?id=17201032242d' target=_blank style='color:#2F92EE;'>#黄金时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103224, encryptionId=17201032242d, topicName=黄金时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Oct 16 23:37:57 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927864, encodeId=7b65192e864e6, content=<a href='/topic/show?id=df0b21902ed' target=_blank style='color:#2F92EE;'>#中国生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21902, encryptionId=df0b21902ed, topicName=中国生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Jun 29 00:37:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410081, encodeId=44ee141008144, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 30 08:37:57 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903343, encodeId=f3b190334383, content=高瞻远瞩, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/0765b63e0e854b47bfde82f80e7001fa/b08a2b82b01a4d3e93e92585f1146052.jpg, createdBy=e4dc2072506, createdName=penhauer, createdTime=Sun Nov 29 17:29:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903208, encodeId=501e903208af, content=生物制剂,未来药物的发展方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/361e8d29e4ed4fdea2379126ea4ed66e/14f645e1dc4a426ea901acffd896920d.jpg, createdBy=faf54736825, createdName=15242b3561m, createdTime=Sun Nov 29 09:11:30 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903155, encodeId=f68790315511, content=加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201126/cd191656b97f470781c0bd36448d9422/aa9a30b60c6646ad94bf6f39648feb47.jpg, createdBy=58b01524016, createdName=355366180, createdTime=Sat Nov 28 22:47:57 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903154, encodeId=3f019031545b, content=希望生物医药有更好的前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83c5439366, createdName=ms7000000371157871, createdTime=Sat Nov 28 22:44:15 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903121, encodeId=15479031215c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Nov 28 19:47:20 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903104, encodeId=25e490310419, content=<a href='/topic/show?id=c15f692604e' target=_blank style='color:#2F92EE;'>#生物医药#</a>勇气,耐心,转型, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69260, encryptionId=c15f692604e, topicName=生物医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Nov 28 17:41:24 CST 2020, time=2020-11-28, status=1, ipAttribution=)]
    2020-11-28 智慧医人

    #生物医药#勇气,耐心,转型

    0

相关资讯

上海市长、发改委副主任及相关部委研究推进生物医药产业发展

上海推进科技创新中心建设办公室12月6日召开第十一次全体会议,总结今年科创中心建设情况,研究推进上海生物医药等产业发展。市委副书记、市长应勇,国家发展改革委副主任林念修共同主持会议并讲话。应勇指出,习近平总书记考察上海重要讲话精神,为上海推进科创中心建设提供了根本遵循。明年是科创中心建设形成基本框架之年,要咬定目标,再接再厉,全力推进,更好发挥创新引领和辐射示范作用。生物医药产业是上海优先发展的重

河南省新增15家新型研发机构 领域涉信息技术、生物医药等

记者从河南省科技厅获悉,郑州信大捷安信息技术股份有限公司等15家新型研发机构已于近日备案,河南省的新型研发机构总数达到82家。此次备案的15家新型研发机构通过省部会商、院地合作、联合共建等多种形式组建,聚焦战略性新兴产业、传统优势产业、区域特色产业需求,主要在信息技术、生物医药、节能环保、新材料、农业等领域为企业和区域产业发展提供科技创新支撑。其中,洛阳智能农业装备研究院有限公司由中国一拖、中联重

上海推动建设研究型医院,支持生物医药产业发展

近日,上海市卫生健康委发布《关于加强本市医疗卫生机构临床研究支持生物医药产业发展的实施方案》,以完善上海市临床研究体系,支持生物医药产业高质量发展。

勃林格殷格翰广撒“英雄帖” 生物医药“创新大赛”正式启动

2019年11月7日,在第二届中国国际进口博览会上,德国药企勃林格殷格翰宣布其创新大赛正式在中国启动, 这是跨国药企在中国主办的首个生物医药类创新竞赛,旨在与中国创新企业或个人展开全方位互动与合作、激励中国本土创新。 “研发创新是我们长期发展的原动力。如今,前所未有的科学创新正在中国频频呈现,这里正迅速成为全世界生物医药研究的创新枢纽。”勃林格殷格翰跨边界研究全球负责人Henri Doods博士充

7家医药企业拟分拆上市,拓宽融资渠道,疫苗业务“受宠”

2020年以来,医药企业分拆上市的节奏进一步加快。

2020年生物医药领域发展趋势预测

2019年,FDA共批准48款创新药,多款first-in-class疗法争相获批,生物类似药快速发展。2019年,医药行业投资热度持续,两起大宗医药并购占据了全年并购金额的2/3,各项技术相继走向成熟,小型药企的临床试验呈现积极结果。步入2020年,生物医药行业将会如何发展,以下五点值得关注。